Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
5.06
-0.21 (-4.08%)
May 15, 2026, 4:00 PM EDT - Market closed
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,972,131
Market Cap
15.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Lipocine | 14 |
| Cocrystal Pharma | 10 |
CVKD News
- 8 days ago - Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA - GlobeNewsWire
- 15 days ago - Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA - TheFly
- 15 days ago - Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) - GlobeNewsWire
- 24 days ago - Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders - TheFly
- 5 weeks ago - Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright - TheFly
- 6 weeks ago - Cadrenal Therapeutics Inc trading halted, volatility trading pause - TheFly
- 6 weeks ago - Cadrenal Therapeutics Inc trading resumes - TheFly
- 6 weeks ago - Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting - GlobeNewsWire